CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for RA in a cohort of patients cared for by rheumatologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
• Be at least 18 years of age or older.
• Be able and willing to provide written consent for participation in the registry as well as Personally Identifiable Information (PII) that includes Full Name and Date of Birth at a minimum.
• Have been diagnosed with rheumatoid arthritis by a rheumatologist.
• Meet at least one of the following criteria:
⁃ (A) Currently receiving an Eligible Medication\*\* that was started within 365 days of the Enrollment Visit.
⁃ i. A temporary interruption of an Eligible Medication is allowed if the interruption in treatment lasted \<180 days.
⁃ (B) Prescribed or receiving the first dose of an Eligible Medication\*\* on the day of the Enrollment Visit.
⁃ (C) Diagnosed with RA within 365 days of the Enrollment Visit regardless of treatment regimen (Early RA).